Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 101–200 of 932
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells
van Nieuwenhuijzen, N., Spaan, I., Raymakers, R. A. P., & Peperzak, V. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3115 · Cited by 129
“In contrast, del(13) is practically absent in MGUS with t(6;14) and t(11;14) translocations but common in MM patients carrying either translocation (40% and 67%, respectively), implicating del(13) in MGUS-toMM progression (26).”
BackgroundKyle, R. A., & Rajkumar, S. V. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06873.x · Cited by 130
“Patients with more than 10% bone marrow plasma cells or an M spike >30 g/l represent SMM, which will be discussed later.”
BackgroundInfluentialSelf-citationBladé, J., Dimopoulos, M., Rosiñol, L., Rajkumar, S. V., & Kyle, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2257 · Cited by 115
“The critical factor for progression is the plasma cell number in that the extent of BMPC involvement is even more critical than the M-protein size.(12) Table 3.”
InfluentialSelf-citationWnt signaling in multiple myeloma: a central player in disease with therapeutic potential
Spaan, I., Raymakers, R. A., van de Stolpe, A., & Peperzak, V. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0615-3 · Cited by 115
“Intramedullary MM may first present in an asymptomatic phase, often referred to as smoldering myeloma (SMM), but progression to active disease is significant within the first 5 years after onset [4].”
BackgroundMultiple myeloma: diagnosis and treatment.
Nau, K. C., & Lewis, W. D. (2008) · PubMed · Cited by 142
Schuster, S. R., Rajkumar, S. V., Dispenzieri, A., Morice, W., Aspitia, A. M., Ansell, S., Kyle, R., & Mikhael, J. (2010) · American Journal of Hematology · doi:10.1002/ajh.21845 · Cited by 111
Self-citationWillrich, M. A. V., & Katzmann, J. A. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0580 · Cited by 121
López‐Corral, L., Sarasquete, M. E., Beà, S., García‐Sánz, R., Mateos, M., Corchete, L. A., Sayagués, J. M., García, E., Bladé, J., Oriol, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.128 · Cited by 111
Barlogie, B., van Rhee, F., Shaughnessy, J. D., Epstein, J., Yaccoby, S., Pineda-Roman, M., Hollmig, K., Alsayed, Y., Hoering, A., Szymonifka, J., et al. (2008) · Blood · doi:10.1182/blood-2008-06-164228 · Cited by 102
Siontis, B. L., Kumar, S. K., Dispenzieri, A. A., Drake, M. T., Lacy, M. Q., Buadi, F. K., Dingli, D., Kapoor, P., Gonsalves, W. I., Gertz, M. A., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.87 · Cited by 105
Self-citationJayaweera, S. P. E., Kanakanamge, S. P. W., Rajalingam, D., & Silva, G. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740796 · Cited by 107
Witzig, T. E., Laumann, K. M., Lacy, M. Q., Hayman, S. R., Dispenzieri, A., Kumar, S., Reeder, C. B., Roy, V, Lust, J. A., Gertz, M. A., et al. (2013) · Leukemia · doi:10.1038/leu.2012.236 · Cited by 100
Self-citationD'Arena, G. F., Gobbi, P. G., Broglia, C. M., Sacchi, S., Quarta, G., Baldini, L., Iannitto, E., Falcone, A. P., Guariglia, R., Pietrantuono, G., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.553000 · Cited by 99
“The follow-up of at least 5 years that our patients underwent is the period in which the risk of transforming into overt, symptomatic MM is higher [16].”
BackgroundResultInfluentialModeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
Cherry, B. M., Korde, N., Kwok, M., Manasanch, E. E., Bhutani, M., Mulquin, M., Zuchlinski, D., Yancey, M. A., Maric, I., Calvo, K. R., et al. (2013) · Leukemia & Lymphoma · doi:10.3109/10428194.2013.764419 · Cited by 99
Treatment of newly diagnosed myeloma
Palumbo, A., & Rajkumar, S. V. (2009) · Leukemia · doi:10.1038/leu.2008.325 · Cited by 95
“The significant risk factors for progression included the amount of monoclonal protein and the extend of bone marrow involvement.(4) No differences in overall survival were noted in patients with de novo myeloma or in those with a preceding diagnosis of plasma cell disorder such as MGUS or smoldering myeloma.”
Self-citationComenzo, R. L. (2009) · Blood · doi:10.1182/blood-2009-04-202879 · Cited by 95
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Witzig, T. E., Moon‐Tasson, L. L., Dinarello, C. A., & Donovan, K. A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24352 · Cited by 92
“The patients enrolled in this trial were at high risk for progression to active MM with 81% having 20% plasma cells and 98% having 10% plasma cells [18].”
BackgroundPI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
Ramakrishnan, V., & Kumar, S. (2018) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1421760 · Cited by 89
Prevalence of smoldering multiple myeloma based on nationwide screening
Thorsteinsdóttir, S., Gíslason, G. K., Aspelund, T., Rögnvaldsson, S., Óskarsson, J. Þ., Sigurðardóttir, G. Á., Þórðardóttir, Á. R., Viðarsson, B., Önundarson, P. T., Agnarsson, B. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02183-6 · Cited by 93
Agarwal, A., & Ghobrial, I. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2922 · Cited by 105
“125 to 8, and ≥ 10% plasma cells in the bone marrow are considered as adverse factors in this model (55, 56).”
BackgroundPaiva, B., Vídriales, M., Rosiñol, L., Martínez‐López, J., Mateos, M., Ocio, E. M., Montalbán, M.-Á., Cordón, L., Gutierrez, N. C., Corchete, L. A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.166 · Cited by 98
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
Lejeune, M., Köse, M. C., Duray, E., Einsele, H., Beguin, Y., & Caers, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00762 · Cited by 87
Landgren, O. (2013) · Hematology · doi:10.1182/asheducation-2013.1.478 · Cited by 87
Treatment for High-Risk Smoldering Myeloma
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1310911 · Cited by 88
Smoldering multiple myeloma current treatment algorithms
Rajkumar, S. V., Kumar, S., Lonial, S., & Mateos, M. V. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00719-0 · Cited by 74
“This rough estimate can be further refined using a variety of common variables, including the size and type of monoclonal protein, and the extent of bone marrow involvement [9].”
BackgroundSelf-citationManagement of older adults with multiple myeloma
Palumbo, A. P., & Mina, R. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.04.001 · Cited by 91
Novel strategies to target the ubiquitin proteasome system in multiple myeloma
Lub, S., Maes, K., Menu, E., Bruyne, E. D., Vanderkerken, K., & Valckenborgh, E. V. (2015) · Oncotarget · doi:10.18632/oncotarget.6658 · Cited by 98
“Up till now SMM patients were closely monitored until the disease progresses to symptomatic MM, after which treatment was initiated [15, 22].”
BackgroundPlasma cell neoplasms and related entities—evolution in diagnosis and classification
Fend, F., Doǧan, A., & Cook, J. R. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03431-3 · Cited by 94
“Recent years have shown that the progression risk of SMM, overall about 10%/year and thus tenfold higher than for MGUS, varies widely [37].”
BackgroundTiming of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context
Chiecchio, L., Dagrada, G. P., Ibrahim, A. H., Cabanas, E. D., Protheroe, R. K. M., Stockley, D. M., Orchard, K. H., Cross, N. C. P., Harrison, C. J., Ross, F. M., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011064 · Cited by 86
Landgren, O., Kyle, R. A., & Rajkumar, S. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1822 · Cited by 96
“1 years) and 25% (median TTP 10 years), respectively (12, 26).”
Self-citationThe Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future
Pozzi, S., & Raje, N. S. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0225 · Cited by 92
Smoldering multiple myeloma requiring treatment: time for a new definition?
Dispenzieri, A., Stewart, A. K., Chanan-Khan, A., Rajkumar, S. V., Kyle, R. A., Fonseca, R., Kapoor, P., Bergsagel, P. L., McCurdy, A., Gertz, M. A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-520890 · Cited by 82
“(A) SMM risk based on BMPCs$ 10%, M protein$ 30 g/L.(21) Bold solid line, both above threshold; solid line, BMPCs$ 10% but M-protein, 30 g/L; dashed line, BMPC, 10% but M-protein$ 30 g/L.”
BackgroundSelf-citationHo, M., Patel, A. S., Goh, C. Y., Moscvin, M., Zhang, L., & Bianchi, G. (2020) · Leukemia · doi:10.1038/s41375-020-01051-x · Cited by 88
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
Heider, M., Nickel, K., Högner, M., & Bassermann, F. C. (2021) · Oncology Research and Treatment · doi:10.1159/000520312 · Cited by 95
Shimanovsky, A., Alvarez, A. J., Murali, S., & Dasanu, C. A. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.05.004 · Cited by 85
Paiva, B., Mateos, M., Sánchez‐Abarca, L. I., Puig, N., Vídriales, M., López‐Corral, L., Corchete, L. A., Hernández, M., Bargay, J., de Arriba, F., et al. (2015) · Blood · doi:10.1182/blood-2015-10-662320 · Cited by 90
Gonsalves, W. I., Rajkumar, S. V., Dispenzieri, A. A., Dingli, D., Timm, M., Morice, W. G., Lacy, M. Q., Buadi, F. K., Go, R. S., Leung, N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.205 · Cited by 87
Self-citationPaiva, B., Gutiérrez, N.-C., Chen, X., Vídriales, M., Montalbán, M.-Á., Rosiñol, L., Oriol, A., Martínez‐López, J., Mateos, M., López‐Corral, L., et al. (2012) · Leukemia · doi:10.1038/leu.2012.42 · Cited by 88
Boiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 86
“For example, within-patient DE identified significant upregulation of FGFR3 and WHSC1 in our patient with t(4;14).”
BackgroundResultInfluentialKastritis, E., Zagouri, F., Symeonidis, A. S., Ρούσσου, Μ., Sioni, A., Pouli, A. G., Delimpasi, S., Katodritou, E., Michalis, E., Michael, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.110 · Cited by 85
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
Ravi, P., Kumar, S., Larsen, J. T., Gonsalves, W., Buadi, F., Lacy, M. Q., Go, R., Dispenzieri, A., Kapoor, P., Lust, J. A., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.65 · Cited by 77
Self-citationPalumbo, A. P., Attal, M., & Roussel, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1925 · Cited by 82
“org Clin Cancer Res; 17(6) March 15, 2011 1259”
BackgroundInfluentialKyle, R. A., & Rajkumar, S. V. (2011) · PubMed · Cited by 91
Self-citationAbduh, M. S. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103920 · Cited by 82
“The chance of developing a malignancy in the first five years after diagnosis, which is 10 % in SMM compared to 1 % in MGUS yearly, is the primary clinical difference between SMM and MGUS (Kyle et al., 2007).”
BackgroundMonoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Kyle, R. A., Miguel, J. F. S., Mateos, M., & Rajkumar, S. V. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.005 · Cited by 81
Self-citationCurrent applications of multiparameter flow cytometry in plasma cell disorders
Jelínek, T., Bezděková, R., Zátopková, M., Burgos, L., Šimíček, M., Ševčíková, T., Paiva, B., & Hájek, R. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.90 · Cited by 78
Jolles, S. R. A., Michallet, M., Agostini, C., Albert, M. H., Edgar, D., Ria, R., Trentin, L., & Lévy, V. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13580 · Cited by 74
“to 85% of patients with CLL develop hypogammaglobulinaemia.(2,4) Approximately 22% of mortalities in MM and 50% of mortalities in CLL are due to infections likely resulting from immunodeficiency.”
BackgroundBrighton, T. A., Khot, A., Harrison, S. J., Ghez, D., Weiss, B. M., Kirsch, A., Magen, H., Gironella, M., Oriol, A., Streetly, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3470 · Cited by 71
“At the time of study protocol development, high-risk SMM was defined as patients having both serum monoclonal M-protein 3 g/dL and bone marrow plasma cells (BMPC) 10% (4).”
BackgroundInfluentialTumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease
Zhang, L., Lei, Q., Wang, H., Xu, C., Liu, T., Kong, F., Yang, C., Yan, G., Sun, L., Zhao, A., et al. (2019) · Theranostics · doi:10.7150/thno.27550 · Cited by 71
“Currently, there is an ongoing dilemma in the management of patients with smoldering MM (SMM), which is an intermediate clinically-defined stage associated with a much higher risk of progression to malignancy (~10% per year) than monoclonal gammopathy of undetermined significance (MGUS; ~1% per year) [54, 55].”
BackgroundImmune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.017 · Cited by 70
Willrich, M. A. V., Murray, D. L., & Kyle, R. A. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.05.001 · Cited by 78
Self-citationMGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology
Mateos, M., & Landgren, O. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_1 · Cited by 69
Offidani, M., Corvatta, L., Morè, S., Nappi, D., Martinelli, G., Olivieri, A., & Cerchione, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624661 · Cited by 71
“Since the risk of progression for this disease is not uniform over time (32), several studies have been conducted with the aim of recognizing predictive factors and thus of evaluating the risk of progression (33–35).”
BackgroundSchinke, C., Poos, A. M., Bauer, M., John, L., Johnson, S., Deshpande, S., Carrillo, L. F., Alapat, D. V., Rasche, L., Thanendrarajan, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007217 · Cited by 75
Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study
Sørrig, R., Klausen, T. W., Salomo, M., Vangsted, A. J., Østergaard, B., Gregersen, H., Frølund, U. C., Andersen, N. F., Helleberg, C., Andersen, K., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12728 · Cited by 68
“The Mayo Clinic study used an average of the aspirate and biopsy estimates of BMPC%, which could therefore possibly result in a lower median BMPC% count than in our cohort (5, 17).”
ResultDNA methylation of microRNA genes in multiple myeloma
Wong, K. Y., Huang, X., & Chim, C. S. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs212 · Cited by 68
“About 15% of all newly diagnosed MM patients are preceded by an additional intermediate stage, known as smoldering MM (SMM), which will evolve into symptomatic MM at a higher rate of 10% per year (5).”
BackgroundEvolving diagnostic criteria for multiple myeloma
Rajkumar, S. V. (2015) · Hematology · doi:10.1182/asheducation-2015.1.272 · Cited by 72
“Bone marrow clonal plasma cells 10% and any one or more of the following: Serum M protein 30 g/L IgA SMM Immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes Serum involved/uninvolved free light chain ratio 8 (but 100) Progressive increase in M protein level (evolving type of SMM)* Bone marrow clonal p…”
Self-citationEvolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
de Larrea, C. F., Isola, I., Pereira, A., Cibeira, M. T., Magnano, L., Tovar, N., Rodríguez‐Lobato, L. G., Calvo, X., Aróstegui, J. I., Díaz, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0013-4 · Cited by 71
Díaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., García‐Sánz, R., Mateos, M., Garayoa, M., & Paíno, T. (2021) · Cancers · doi:10.3390/cancers13061353 · Cited by 70
“Moreover, the risk of progression to symptomatic MM from presymptomatic stages (MGUS and SMM) is directly related to the proportion of normal bone marrow plasma cells at diagnosis [64].”
Backgroundvan de Donk, N. W. C. J., Mutis, T., Poddighe, P. J., Lokhorst, H. M., & Zweegman, S. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12504 · Cited by 74
“This contrasts with MGUS, in which the rate of progression is constant over time [47].”
BackgroundMateos, M.-V., Hernández, M.-T., Salvador, C., Rubia, J. D. L., de Arriba, F., López-Corral, L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.030 · Cited by 59
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Kyle, R. A., & Rajkumar, S. V. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0047-9 · Cited by 61
Self-citationMultiple myeloma – an update on diagnosis and treatment
Caers, J., Broek, I. V., Raeve, H. D., Michaux, L., Trullemans, F., Schots, R., Camp, B. V., & Vanderkerken, K. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01127.x · Cited by 75
MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis
Pourhanifeh, M. H., Mahjoubin‐Tehran, M., Shafiee, A., Hajighadimi, S., Moradizarmehri, S., Mirzaei, H., & Asemi, Z. (2019) · IUBMB Life · doi:10.1002/iub.2211 · Cited by 62
“It is estimated that, for the first 5 years, progression risk from MM to SMM is approximately 10% per year, during the subsequent 5 years is about 5% per year, and thereafter 1% per year for the following 10 years.(7) The development and onset of MM is driven by numerous genetic aberrations, such as point mutations, a…”
BackgroundInfluentialBeta‐2‐microglobulin is an independent predictor of progression in asymptomatic multiple myeloma
Rossi, D., Fangazio, M., Paoli, L. D., Puma, A., Riccomagno, P., Pinto, V. M., Zigrossi, P., Ramponi, A., Monga, G., & Gaïdano, G. (2010) · Cancer · doi:10.1002/cncr.24959 · Cited by 81
“sMC, BMPC percentage, and FLC burden, measured in serum or estimated by BJ proteinuria, are among the most widely recognized risk factors of asymptomatic MM progression.(8,12,15) Our results document that B2M improves the risk stratification model defined by sMC, uMC, and BMPC percentage by adding information both in…”
BackgroundMethodResultInfluentialEpidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 70
“For SM, the annual risk of progression to MM is 10% for the first 5 years after a diagnosis, 3% for the subsequent 5 years, and 1% thereafter.(138) However, risks vary within these groups and individuals with MGUS and SM should therefore undergo risk stratification to determine the risk of developing MM or an associat…”
BackgroundSerum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
Visram, A., Soof, C. M., Rajkumar, S. V., Kumar, S. K., Bujarski, S. E., Spektor, T. M., Kyle, R. A., Berenson, J. R., & Dispenzieri, A. A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00505-4 · Cited by 63
“In SMM patients, the risk of progression to MM is ~10% per year for the first 5 years post diagnosis, 3% per year for the subsequent 5 years, and 1% per year thereafter [11].”
BackgroundSelf-citationMicrobiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer
Bellone, M., Brevi, A., & Huber, S. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00064-19 · Cited by 65
Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment
Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3366 · Cited by 60
Tete, S. M., Bijl, M., Sahota, S. S., & Bos, N. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00257 · Cited by 62
“Hypogammaglobulinemia occurs at a lower frequency in MGUS (25–28%) (3, 86, 87), is more frequent in SMM (45–83%) (17, 88, 89) and is often associated with MM (25, 90).”
BackgroundKhan, R., Dhodapkar, M., Rosenthal, A., Heuck, C., Papanikolaou, X., Qu, P., van Rhee, F., Zangari, M., Jethava, Y., Epstein, J., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124651 · Cited by 56
Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus
Klatt, E. C., & Kumar, V. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4930-2.00013-x · Cited by 58
Gonsalves, W. I., Ramakrishnan, V., Hitosugi, T., Ghosh, T., Jevremovic, D., Dutta, T., Sakrikar, D., Petterson, X.-M., Wellik, L., Kumar, S. K., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94543 · Cited by 57
“MGUS progresses to MM at a rate of 1% per year (24), whereas SMM has a much higher rate of progression of 10% per year for the first 5 years, 3% per year for the next 5 years, and then 1% per year thereafter (25).”
BackgroundDeciphering the chronology of copy number alterations in Multiple Myeloma
Aktas Samur, A., Minvielle, S., Shammas, M., Fulciniti, M., Magrangeas, F., Richardson, P. G., Moreau, P., Attal, M., Anderson, K. C., Parmigiani, G., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0199-3 · Cited by 56
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Bolli, N., Genuardi, E., Ziccheddu, B., Martello, M., Oliva, S., & Terragna, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00189 · Cited by 63
Multiple Myeloma Precursor Disease
Landgren, O., & Waxman, A. J. (2010) · JAMA · doi:10.1001/jama.2010.1713 · Cited by 55
“At 5-year assessment, risk of progression to multiple myeloma was 25%, 51%, and 76% for patients with 1, 2, or 3 risk factors, respectively.(10,30) In contrast, the risk stratification scheme of the PETHEMA study group has focused on the use of multiparameter flow cytometry of the bone marrow to quantify the ratio of…”
Rajkumar, S. V., Merlini, G., & Miguel, J. F. S. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.128 · Cited by 63
Self-citationChiecchio, L., Dagrada, G. P., Protheroe, R. K. M., Stockley, D. M., Smith, A. G., Orchard, K. H., Cross, N. C. P., Harrison, C. J., Ross, F. M., & Forum, O. B. O. T. U. M. (2009) · Haematologica · doi:10.3324/haematol.2008.004440 · Cited by 56
“It is not clear whether loss of der(14) occurred at the time of t(4;14) formation or was a secondary change, although no signal pat-”
BackgroundResultInfluentialSiragusa, S. M., Morice, W. G., Gertz, M. A., Kyle, R. A., Greipp, P. R., Lust, J. A., Witzig, T. E., Lacy, M. Q., Zeldenrust, S. R., Rajkumar, S. V., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1028-8 · Cited by 55
“Study population was selected from the Mayo Clinic Dysproteinemia database (Division of Hematology, Rochester MN, USA) by a computerized search of the medical records of consecutive patients with diagnosis of MM and SM during the period January 1, 1993 to December 31, 2003: Diagnosis was made upon criteria on the Inte…”
MethodSelf-citationTermini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1594 · Cited by 54
Abramson, H. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155192 · Cited by 57
“Progression from MGUS to MM, which carries a risk of about 1% per year [2], may also include another asymptomatic state known as smoldering myeloma [3].”
BackgroundAl‐Farsi, K. (2013) · Oman Medical Journal · doi:10.5001/omj.2013.02 · Cited by 61
Multiple myeloma in the very elderly patient: challenges and solutions
King, A. J., Eyre, T. A., Sharpley, F. A., Watson, C. S., Ramasamy, K., & Willan, J. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s89465 · Cited by 58
“Similarly, patients with smoldering myeloma (patients meeting the diagnostic criteria for myeloma in terms of their paraprotein level and/or marrow plasma cell percentage but without resulting end-organ damage) do not require treatment, although they have a 50% risk of requiring treatment over the next 5 years.(19,20)…”
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A. A., Melton, L. J., Benson, J. T., Kumar, S. K., & Rajkumar, S. V. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70001-8 · Cited by 53
Self-citationHow I treat smoldering multiple myeloma
Ghobrial, I. M., & Landgren, O. (2014) · Blood · doi:10.1182/blood-2014-08-551549 · Cited by 58
Genomic analysis of high-risk smoldering multiple myeloma
Lopez-Corral, L., Mateos, M. V., Corchete, L. A., Sarasquete, M. E., de la Rubia, J., de Arriba, F., Lahuerta, J.-J., Garcia-Sanz, R., San Miguel, J. F., & Gutierrez, N. C. (2012) · Haematologica · doi:10.3324/haematol.2011.060780 · Cited by 51
“HR-SMM were defined by the presence of more than 10% PCs in BM and an MC of IgG more than 3 g/dL, IgA more than 2 g/dL, or Bence Jones proteinuria more than 1 g/24 h together with the absence of CRAB.(2) Patients meeting either, but not both, of these two criteria were also included in the study if they met the additi…”
BackgroundInfluentialInsights on Multiple Myeloma Treatment Strategies
Mateos, M., Ludwig, H., Bazarbachi, A. A., Beksaç, M., Bladé, J., Boccadoro, M., Cavo, M., Delforge, M., Dimopoulos, M. A., Facon, T. T. F., et al. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000163 · Cited by 55
Monoclonal Gammopathy of Undetermined Significance
Gonsalves, W. I., & Rajkumar, S. V. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202212200 · Cited by 53
Self-citationCastillo, J. J. (2016) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2016.07.002 · Cited by 53
“The rate of progression to active MM or AL amyloidosis occurs at a rate of 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% to 2% per year for the following 10 years.(38) Three factors have been associated with progression from smoldering to active MM: abnormal”
BackgroundAbe, Y., Ikeda, S., Kitadate, A., Narita, K., Kobayashi, H., Miura, D., Takeuchi, M., O’uchi, E., O’uchi, T., & Matsue, K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04312-9 · Cited by 52
Bergstrom, D. J., Kotb, R. R., Louzada, M., Sutherland, H. J., Tavoularis, S., Venner, C. P., Côté, J. A., LeBlanc, R., Reiman, T., Sébag, M., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.017 · Cited by 60
“The risk of evolution to symptomatic disease rises with increasing clonal PC burden and is defined as smoldering MM (SMM), an intermediate stage associated with a higher risk of progression to overt MM (w10% per year).(9,11)”
BackgroundAnti-Cancer Activity of Curcumin on Multiple Myeloma
Mirzaei, H., Bagheri, H., Ghasemi, F., Khoi, J. M., Pourhanifeh, M. H., Heyden, Y. V., Mortezapour, E., Nikdasti, A., Jeandet, P., Khan, H. Z., et al. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200918113625 · Cited by 55
Musto, P., Engelhardt, M. M., Caers, J., Bolli, N., Kaiser, M., van de Donk, N. W. C. J., Terpos, E., Broijl, A., de Larrea, C. F., Gay, F., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278519 · Cited by 53
“4 cases per 100,000 persons and a higher prevalence in Americans of African descent.(6,7) The median time to progression to active MM is around 5 years, with a variable rate of approximately 10%/year during the first 5 years, 3%/year for the next 5 years, and 1%/year thereafter.”
BackgroundMulti-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Cheng, Y., Sun, F., Alapat, D. V., Wanchai, V., Mery, D. E., Siegel, E. R., Xu, H., Johnson, S., Guo, W., Bailey, C., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01172-x · Cited by 57
“The disease progresses from the precursor stages, monoclonal gammopathy of undetermined signi fi cance (MGUS) and smoldering MM (SMM) with average progression rates at 1% and 10% per year during the fi rst 5 years, respectively [2, 3].”
Wichert, S., Juliusson, G., Johansson, Å. C. M., Sonesson, E., Teige, I., Wickenberg, A. T., Frendéus, B., Korsgren, M., & Hansson, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171205 · Cited by 50
Wu, V., Moshier, E. L., Leng, S., Barlogie, B., Cho, H. J., Jagannath, S., Madduri, D., Mazumdar, M., Parekh, S. S., & Chari, A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016998 · Cited by 50
“Only 21 patients had to be censored at the time they began treatment of non-calcium elevation, renal dysfunction, anemia, and bone disease indications including infection (1), amyloid (2), rapid increase in paraprotein (4), BMPC $60 or FLCr $100 (7), other (4), and unknown (3).”
BackgroundMoving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review
Maura, F., Bolli, N., Rustad, E. H., Hultcrantz, M., Munshi, N., & Landgren, O. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4659 · Cited by 53
Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?
Lamers, J., Hartmann, M., Goldschmidt, H., Brechtel, A., Hillengaß, J., & Herzog, W. (2013) · Psycho-Oncology · doi:10.1002/pon.3284 · Cited by 50
Singh, G. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa153 · Cited by 58
Kazandjian, D., Hill, E., Dew, A., Morrison, C., Roswarski, J., Korde, N., Emanuel, M., Petrosyan, A., Bhutani, M., Calvo, K. R., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3971 · Cited by 49
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.